Pilva, a Croatian pharmaceutical company owned by Israeli company Teva Pharmaceuticals (IW 1000/224), announced yesterday that it has opened a new capsules and tablets manufacturing factility in Croatia.
The new facility at the production site in Zagreb, representing an investment of $100 million, will increase the company’s production capacities by 2 billion tablets or more than 25%.
Medicinal products manufactured in the new production facility are mainly intended for EU and USA markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.
"This year has been especially important for us - we are about to complete one of the largest investment cycles in the company's history,” said Tihomir Orešković, president of PLIVA's Management Board. “ I am glad that Teva is today one of the biggest private investors in Croatia and that its investments in the production facilities in Zagreb and Savski Marof total more than $200 million.”
About 200 new jobs will be added.
